How has the dry powder inhaler market evolved, and where is it heading next?
The dry powder inhaler market size has grown strongly in recent years. It will grow from $21.25 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to renewed interest in sustainable building materials, cultural preservation and heritage restoration, rise in green building practices, local sourcing and community involvement, regulatory support and building codes.
The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $27.13 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies, global economic factors. Major trends in the forecast period include increased research and development, renewed interest in traditional building techniques, advancements in material technology, architectural and design trends, regulatory support for sustainable construction.
Get Your Free Sample of The Global Dry Powder Inhaler Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13430&type=smp
How have varous drivers impacted the growth of the dry powder inhaler market?
The growing prevalence of respiratory diseases is expected to propel the growth of the dry powder inhaler market going forward. Respiratory diseases refer to respiratory disorders or lung diseases, encompassing a broad category of medical conditions affecting the respiratory system. Dry powder inhalers are essential in treating respiratory conditions such as asthma, COPD, and cystic fibrosis as they deliver medicine directly to the lungs, where it is most effective. It is a promising alternative to traditional drug delivery methods for respiratory diseases. For instance, in December 2023, according to a research study published by JAMA Network Open, a medical journal by the American Medical Association, the global burden of chronic obstructive pulmonary disease (copd) projected that COPD cases worldwide could reach nearly 600 million by 2050, marking a 23% increase in prevalence. Among these the number of female cases is expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Furthermore, the majority of cases are anticipated in low- and middle-income regions, where the prevalence will more than double that of high-income regions by 2050. Therefore, the growing prevalence of respiratory diseases will drive the growth of the dry powder inhaler market.
What are the primary segments of the dry powder inhaler market?
The dry powder inhaler market covered in this report is segmented –
1) By Product: Single-Dose Inhalers, Multi-Dose Inhalers
2) By Function: Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Other Applications
4) By End User: Hospitals And Clinics, Homecare Settings, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Single-Dose Inhalers: Capsule-Based Inhalers, Diskus-Based Inhalers
2) By Multi-Dose Inhalers: Blister-Based Inhalers, Rotahaler-Based Inhalers
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/dry-powder-inhaler-global-market-report
Which firms are leading the dry powder inhaler market?
Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.
How will industry trends affect the trajectory of the dry powder inhaler market?
Major companies operating in the dry powder inhaler market are developing innovative products with muscarinic antagonist for treating chronic obstructive pulmonary disease (COPD) and expanding their product portfolio. A muscarinic antagonist is a drug that inhibits the muscarinic acetylcholine receptor. It controls and treats various illnesses, such as COPD and organophosphate poisoning. For instance, In March 2024, Berry Global, a US-based company known for developing and manufacturing a wide range of flexible packaging solutions, launched its new dry powder inhaler at Pharma pack. The inhaler is designed to enhance drug delivery for respiratory conditions like COPD and asthma, offering a customizable solution for pharmaceutical companies.
Which geographic trends are shaping the dry powder inhaler market, and which region has the highest market share?
North America was the largest region in the dry powder inhaler market in 2024. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Dry Powder Inhaler Market Report 2025 Offer?
The dry powder inhaler market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A dry powder inhaler (DPI) refers to a medical device used for delivering medication directly to the lungs in the form of dry powder. It is designed to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). It is essential for the user to inhale rapidly and deeply to enable the medication to reach the lungs to utilize a DPI effectively.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13430
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
